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Background
• Despite promising cancer results from immune 
checkpoint inhibitors (ICI) several immune related 
adverse events (irAE) have been observed, including 
myocarditis. 
• Though it has a  low incidence, 0.5 to 1%, ICI 
myocarditis is the most fatal irAE with a reported 
mortality of 25 to 50%. 
• ICI myocarditis diagnosis depends on a combination of 
clinical presentation: biomarkers, cardiac imaging, and 
endomyocardial biopsy.
• The clinical presentation of myocarditis is often equated 
with heart failure despite most patients presenting with 
normal left ventricular ejection fraction (LVEF). 
• Current practice guidelines suggest to first rule coronary 
artery disease (CAD) prior to making a diagnosis of 
myocarditis. 
Methods 
• A single center retrospective cohort study of all patients 
who had endomyocardial biopsy for suspected ICI 
myocarditis between January 2018 and January 2020 
was performed.
• Manual electronic medical record review was 
performed to collect demographics, oncologic history, 
laboratory values, catheterization data, and cardiac 
imaging data. 
• Pulmonary capillary wedge pressure (PWCP) 
≥12mmHg indicates heart failure and 
PCWP<12mmHg indicates no heart failure. 
• Clinical parameters and right heart hemodynamics 
were compared using Chi-square test. 
Results con’t
• 47% presented with dyspnea but presenting 
symptoms of dyspnea and elevated PCWP 
were not associated (p=0.09). 
• Of the 8 patients presenting with dyspnea but 
with normal PCWP, 3 (38%) had concomitant 
myositis, myasthenia gravis, or guillian barre 
irAEs. 
• Significant CAD was found on left heart cath in 
26% of patients presenting with myocarditis but 
the presence of CAD was not associated with 
having elevated PCWP (p=0.14). 
Conclusions
• ICI myocarditis has varied clinical 
presentations including heart failure 
• Only half may actually have heart failure this 
may be present in those with both normal and 
depressed LVEF.
• With patients presenting with dyspnea but have 
normal filling pressures on echocardiogram, 
concomitant muscular/neuromuscular junction 
irAEs should be considered. 
• Cancer and CAD have shared risk factors and 
up to a quarter of patients presenting with 
myocarditis may have concomitant CAD 
• The presence of CAD should not rule out 
myocarditis.  
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Objective 
To establish that the presentation of heart failure may not 
always indicate ICI myocarditis.
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Results 
• 52 patients had endomyocardial biopsy for suspicion of 
ICI myocarditis. 
• The mean age was 68 years and the majority 
were male (75%).
• 42 (81%) patients had definite, probable, or 
possible myocarditis and the remaining were 








Myocarditis Negative for Myocarditis
P-value
Median (IQR)
n=26 n=7 n=9 n=11
Range
Right atrial mean pressure 9 (7-11) 7 (4-9) 5 (5-12) 8 (8-9) 0.44
0-10 0-21 44271
Pulmonary artery systolic 
pressure 32 (26-36) 26 (25 -36) 35 (28-43) 33 (29-40) 0.6
19-46 21-57 24-58 23-54
Pulmonary artery mean 
pressure 20 (18-24) 22 (14-24) 27 (17-32) 22 (19-29) 0.65
13455 14946 13-42 15-35
Pulmonary capillary wedge 
pressure mean 12 (9-15) 11 (8-13) 16 (7-22) 13 (10-16) 0.79
44278 44313 12479 44461
Left ventricular end-diastolic 
pressure 20 (12-22) 17 (14-19) 22 (11-26) 18 (15-19) 0.75
12451 11810 12236 14-20
Cardiac index- Fick 2.8 (2.2-3.1) 2.3 (2.1-2.4) 2.1 (1.8-2.2) 3.1 (2.8-3.2) 0.07
L/min/m2 1.4-3.8 2.1-2.5 1.3-2.3 2.2-3.3
Arterial aortic systolic blood 
pressure 128 (114-144) 138 (122-150) 114 (105-122) 128 (117-132) 0.37
88-169 102-154 89-163 114-164
Demographics & Definite Probable Possible Negative for 
P-value
Clinical Parameters Myocarditis Myocarditis Myocarditis Myocarditis
Range n=26 n=7 n=9 n=11
Age, Median (IQR) 74 (66-77) 62 (58-73) 65 (63-69) 69 (66-76) 0.54
Gender % (M/F) 73/27 71/29 89/11 73/27 0.79
Race % 
0.4
White 73 57 67 27
Black 8 14 0 0
Other 21 28 32 73
• Of those with myocarditis, LVEF <50% was observed in 
47% of patients and pulmonary capillary wedge pressure 
(PCWP) >12 mmHg was observed in 47% of patients 
• Elevated PCWP and LVEF <50% were not correlated 
(p=0.78).
Table 1-Baseline Demographics 
Table 2-Right and Left Heart Catheterization 
Data at Time of Biopsy
